- Details
- Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and the VOLGA trial exploring ctDNA clearance as a biomarker. Dr. De Santis highlights the promising results of TAR-200, a novel gemcitabine intravesical system, which shows high complete...
|
- Details
- Andrea Necchi discusses the SunRISe-4 trial results, evaluating TAR-200 (an intravesical gemcitabine-releasing device) combined with cetrelimab (anti-PD-1) in cisplatin-ineligible muscle-invasive bladder cancer patients. The study shows promising efficacy with a 42% pathological complete response rate for the combination therapy, compared to 23% for cetrelimab alone. Dr. Necchi highlights the favo...
|
- Details
- Matthew Galsky discusses preliminary results from the RC48G001 Study Cohort C, evaluating disitamab vedotin plus pembrolizumab in HER2-expressing metastatic urothelial cancer. The study shows a 75% response rate in treatment-naive patients, with activity observed in both HER2-positive and HER2-low tumors. The safety profile differs from enfortumab vedotin plus pembrolizumab, potentially offering a...
|
- Details
- Andrea Apolo discusses extended follow-up data from the AMBASSADOR trial. This phase 3 study evaluates adjuvant pembrolizumab versus observation in high-risk muscle-invasive urothelial carcinoma. With 45-month follow-up, pembrolizumab demonstrates significant improvement in disease-free survival (29.6 vs 14.2 months). The benefit is consistent across PD-L1 status and lymph node involvement subgrou...
|
- Details
- Sam Chang host Mario de Angelis to discuss a study on trimodal therapy (TMT) for urothelial and non-urothelial invasive bladder cancer. Dr. De Angelis presents findings from a SEER database analysis of over 5,000 patients treated with TMT. The study reveals that TMT use has increased for organ-confined urothelial carcinoma but decreased for non-urothelial cases. For organ-confined disease, patient...
|
- Details
- Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...
|
- Details
- Ashish Kamat interviews Omar Alhalabi about research on small cell neuroendocrine carcinoma of the urinary tract. Dr. Alhalabi discusses the study's findings on prognostic factors for relapse in surgically resected cases. The research reveals that neoadjuvant chemotherapy benefits patients, while the persistence of small cell carcinoma at surgery is associated with a high risk of relapse. The stud...
|
- Details
- Sam Chang interviews Elias Chandran about a systematic review and meta-analysis on mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) in urothelial carcinoma. Dr. Chandran presents findings showing higher prevalence of dMMR and MSI-H in upper tract urothelial carcinoma compared to bladder cancer, with greater frequency in localized disease than metastatic disease. The study s...
|
- Details
- Zach Klaassen speaks with Brent Rose about advances in bladder-sparing therapies for localized bladder cancer. Dr. Rose highlights the surprising underutilization of chemo-radiation in bladder cancer treatment, despite its established role in other cancers and the significant risks and quality of life issues associated with cystectomy. He underscores the efficacy of chemo-radiation, drawing on dat...
|
- Details
- Zach Klaassen discusses the findings of the EV-302/KEYNOTE-A39 trial with Michiel Simon Van der Heijden. The trial addresses a critical gap in treatment for cisplatin-ineligible patients with advanced urothelial cancer. Historically, these patients, who often receive carboplatin-based chemotherapy, have faced poorer outcomes compared to those eligible for cisplatin. The EV-302 trial, however, trea...
|
